Jon Winkelried and 2 Others Sells $10M of Sionna Therapeutics Inc (SION) — SEC Form 4, Jan 26, 2026
Open-Market Net Sale · SEC Form 4
−$10,000,000
Equity position changed by -3.7%
Reporting Owners
10%+
10%+
10%+
TXN 2026-01-22
·
FILED 2026-01-26
Equity Position
6.49M sh
6,744,962 → 6,494,962
Equity Change
-3.7%
shares held after vs before
Filing Lag
2 business days
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owners
| Name | Relationship |
|---|---|
| Jon Winkelried CIK 0001366946 |
10% Owner
|
| James G Coulter CIK 0001099776 |
10% Owner
|
| Tpg Gp A, LLC CIK 0001903793 |
10% Owner
|
Jon Winkelried at Sionna Therapeutics Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
$10,000,000
More from this insider at Sionna Therapeutics Inc
| 2025-07-01 | Buy | +$950,400 | View |
| 2025-02-12 | Buy | +$20,250,000 | View |
Non-Derivative Securities Transactions
Footnotes (4)
- F1
- Each of James G. Coulter and Jon Winkelried own entities that control TPG GP A, LLC (together with Messrs. Coulter and Winkelried, the "Reporting Persons"), which exercises direct or indirect control over entities that collectively hold 100% of the shares of Class B common stock (which represents a majority of the combined voting power of the common stock) of TPG Inc., which is the sole member of TPG GPCo, LLC, which is the sole member of TPG Holdings II-A, LLC, which is the general partner of TPG Operating Group II, L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Operating Group I, L.P., which is the sole member of The Rise Fund GenPar Advisors, LLC, which is the general partner of The Rise Fund GenPar, L.P., which is the managing member of The Rise Fund SPV GP, LLC. Show more
- F2
- The Rise Fund SPV GP, LLC is the general partner of each of The Rise Fund Sling, L.P., which directly holds 5,340,931 shares of Common Stock ("Common Stock") of Sionna Therapeutics, Inc. (the "Issuer"), and The Rise Fund Sling II, L.P. (together with The Rise Fund Sling, L.P., the "TPG Funds"), which directly holds 1,154,031 shares of Common Stock. Show more
- F3
- Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each of the TPG Funds and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any Show more
- F4
- Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Show more
Remarks
(5) The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16a-3(j) under the Exchange Act. (6) Gerald Neugebauer is signing on behalf of Messrs. Coulter and Winkelried pursuant to authorization and designation letters dated January 10, 2024, which were previously filed with the Securities and Exchange Commission.
Show moreRelated filings at Sionna Therapeutics Inc
Institutional Holders
13F holders · Jun 30, 2026
145
institutional managers reporting a position
Largest by reported value
- Ra Capital Management, L.P. $436M
- Tpg Gp A, Llc $286M
- Viking Global Investors Lp $141M
5%+ Holders · 13D/G
6 filers
-
Orbimed Advisors Llc 6.6%
-
Tpg Gp A, Llc 15.2%
Other insiders at Sionna Therapeutics Inc
GET /v1/forms/4/0001999371-26-001696
API docs
View Original SEC Filing